ADAC announces new CT simulation package
ADAC Laboratories, a manufacturer of nuclear medicine and radiation therapy planning systems, believes it is tapping into a new market for CT simulation products with the introduction of its SmartSim package. SmartSim is an integrated CT simulation and
ADAC Laboratories, a manufacturer of nuclear medicine and radiation therapy planning systems, believes it is tapping into a new market for CT simulation products with the introduction of its SmartSim package.
SmartSim is an integrated CT simulation and radiation therapy planning package that speeds up the radiation treatment planning process. The SmartSim package is used with ADACs Pinnacle3 radiation therapy planning system.
SmartSim software reconstructs data gathered from CT scans into 3-D images and digitally reconstructed radiographs. This allows radiation oncologists to more accurately pinpoint the location, size, and shape of tumors. Clinicians are then able to determine optimal radiation beam placements to treat cancerous cells while minimizing the risk to nearby healthy tissue, the firm reports. The program uses a single database for simulation and planning.
Shipments of SmartSim began this month. The company expects the market for CT stimulation products to reach about $100 million this year as radiation oncologists use the technology in place of conventional x-ray simulation.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
